Merck KGaA Archives -

News/ News/ News/ Oncology/ R&D

ESMO: Merck claims leap forward in head and neck cancer

Phil Taylor Debiopharm, ESMO 2022, head and neck cancer, Merck KGaA, Oncology 0 Comment

Germany’s Merck KGaA paid $237 million upfront for rights to Debiopharm’s head and neck squamous cell carcinoma (HNSCC)

ESMO: Merck claims leap forward in head and neck cancer

https://pharmaphorum.com/news/esmo-merck-claims-leap-forward-in-head-and-neck-cancer/

xray image of human head with brain and electric pulses

News/ News/ R&D

Sanofi pauses enrolment in ex-US tolebrutinib trials

Phil Taylor BTK inhibitor, evobrutinib, Merck KGaA, multiple sclerosis, safety, Sanofi 0 Comment

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although

Sanofi pauses enrolment in ex-US tolebrutinib trials

https://pharmaphorum.com/news/sanofi-pauses-enrolment-in-ex-us-tolebrutinib-trials/

News/ News/ R&D

Liver injuries prompt clinical hold on Sanofi BTK drug

Phil Taylor Biogen, BTK inhibitor, Merck KGaA, multiple sclerosis, myasthenia gravis, Roche, safety, Sanofi 0 Comment

One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after

Liver injuries prompt clinical hold on Sanofi BTK drug

https://pharmaphorum.com/news/liver-injuries-prompt-clinical-hold-on-sanofi-btk-drug/

Market Access/ News/ News

NICE reverses stance on Merck’s Bavencio for bladder cancer

Phil Taylor Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer 0 Comment

Last year, NICE said that Merck KGaA/Pfizer’s Bavencio was too expensive for routine in NHS use as a

NICE reverses stance on Merck’s Bavencio for bladder cancer

https://pharmaphorum.com/news/nice-reverses-stance-on-mercks-bavencio-for-bladder-cancer/

Digital/ News/ News

Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety tech

Phil Taylor artificial intelligence, BioAI, digital, digital health, drug discovery, Merck KGaA, Quris, safety, Toxicology 0 Comment

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that

Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety tech

https://pharmaphorum.com/news/merck-will-assess-quris-ai-patient-on-a-chip-drug-safety/

Digital/ News/ News

Merck backs startup bringing AI to fertility treatment

Phil Taylor artificial intelligence, digital, digital health, fertility, financing, Future Fertility, Merck KGaA 0 Comment

It’s no secret that fertility treatment is expensive and has a low success rate, placing a big financial

Merck backs startup bringing AI to fertility treatment

https://pharmaphorum.com/news/merck-backs-biotech-bringing-ai-to-fertility-treatment/

News/ News/ Sales and Marketing

Another mRNA company gets snapped up as Merck buys Exelead

Phil Taylor Exelead, M&A, Merck KGaA, mRNA, outsourcing 0 Comment

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has

Another mRNA company gets snapped up as Merck buys Exelead

https://pharmaphorum.com/news/another-mrna-company-gets-snapped-up-as-merck-buys-exelead/

News/ News/ Oncology

GSK bails on $4.2bn partnership with Merck on cancer drug

Phil Taylor bintrafusp alfa, GlaxoSmithKline, immuno-oncology, Merck KGaA, Oncology, partnership 0 Comment

GlaxoSmithKline has ended its collaboration with Germany’s Merck KGaA’s cancer treatment bintrafusp alfa, after a trio of failed

GSK bails on $4.2bn partnership with Merck on cancer drug

https://pharmaphorum.com/news/gsk-bails-on-4-2bn-partnership-with-merck-on-cancer-drug/

News/ News/ Oncology

Third strike for GSK/Merck as bintrafusp alfa flubs again

Phil Taylor biliary tract cancer, bintrafusp alfa, GlaxoSmithKline, immuno-oncology, Merck KGaA, Oncology, partnering 0 Comment

GlaxoSmithKline’s big gamble on Merck KGaA’s bintrafusp alfa has gone from bad to worse, after the drug failed

Third strike for GSK/Merck as bintrafusp alfa flubs again

https://pharmaphorum.com/news/third-strike-for-gsk-merck-cancer-alliance-as-bintrafusp-alfa-flubs-again/

Trending

Merck KGaA

Login